ナミキ商事株式会社 医薬品及び創薬化学品の専門商社

医薬品及び創薬化学品の専門商社

検索検索

バイオ製品Bio Products

タンパク質、抗体、アッセイキット

タンパク質カタログ

輸入に関する法規制チェックは、御見積のご依頼をいただいた際に行います。
法規制によっては、定価として記載の価格に追加の費用が発生する場合や供給出来ない場合がございますので、あらかじめご了承ください。

サプライヤー
AcroBioSystems
カタログNo.
CD0-C52H5
製品名称
Canine CD20 / MS4A1 Full Length Protein, His Tag (Detergent)
タンパク質名
CD20
Species
Canine
HOST
HEK293
20ug: 215,800円
お問い合わせ
100ug: 800,000円
お問い合わせ
500ug: 2,004,700円
お問い合わせ

Overview

Synonyms -
Characteristics This protein carries a polyhistidine tag at the C-terminus. The protein has a calculated MW of 35.2 kDa. The protein migrates as 40 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin Level 1.0 EU per μg
Purity 80%
Description B-lymphocyte antigen CD20 is also known as B-lymphocyte surface antigen B1, Leukocyte surface antigen Leu-16, Membrane-spanning 4-domains subfamily A member 1 and MS4A1, is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R+, CD117+) and progressively increasing in concentration until maturity. CD20 is expressed on all stages of B cell development except the first and last; it is present from late pro-B cells through memory cells, but not on either early pro-B cells or plasma blasts and plasma cells. It is found on B-cell lymphomas, hairy cell leukemia, B-cell chronic lymphocytic leukemia, and melanoma cancer stem cells. The protein has no known natural ligand and its function is to enable optimal B-cell immune response, specifically against T-independent antigens. It is suspected that it acts as a calcium channel in the cell membrane. CD20 / MS4A1 is the target of the monoclonal antibodies (mAb) rituximab, Ibritumomab tiuxetan, and tositumomab, which are all active agents in the treatment of all B cell lymphomas and leukemias. Defects in CD20 / MS4A1 are the cause of immunodeficiency common variable type 5 (CVID5); also called antibody deficiency due to CD20 defect. CVID5 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen.
Reference -
URL https://www.acrobiosystems.com/products/protein/cd20-canine-cd0-c52h5

お問い合わせリスト(-)

お問い合わせフォーム